FCGRT and chronic inflammatory demyelinating polyradiculoneuropathy: Background Efgartigimod is a neonatal Fc receptor (FcRn) antagonist approved for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody-positive, and for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).